Beam Therapeutics Inc. (NASDAQ:BEAM – Get Rating) CFO Terry-Ann Burrell sold 2,454 shares of the business’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $30.31, for a total value of $74,380.74. Following the completion of the transaction, the chief financial officer now owns 49,303 […]
Beam Therapeutics Inc. (NASDAQ:BEAM – Get Rating) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 13,910,000 shares, an increase of 11.5% from the February 28th total of 12,480,000 shares. Based on an average trading volume of 908,500 shares, the days-to-cover ratio is […]
Should You Buy or Sell Beam Therapeutics Stock? Get The Latest BEAM Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Sanford C. Bernstein assumed coverage on shares of Beam Therapeutics (NASDAQ:BEAM – Get Rating) in a research note released on Tuesday, The Fly reports. The firm issued a market perform rating and a $37.00 target price on the stock. Several other equities analysts also recently weighed in on the company. BMO Capital Markets raised Beam […]
Beam Therapeutics (NASDAQ:BEAM – Get Rating)‘s stock had its “outperform” rating reiterated by analysts at William Blair in a research note issued on Wednesday, PriceTargets.com reports. A number of other analysts have also weighed in on BEAM. Cantor Fitzgerald assumed coverage on shares of Beam Therapeutics in a research report on Tuesday, January 31st. They […]